Jay Feingold

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio et al. · The Lancet Oncology · 2021 · 397 citations

Loncastuximab Tesirine, Lymphoid Neoplasia, Hematological Malignancy +6

Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies

Janice P. Dutcher, Paul de Souza, David F. McDermott et al. · Medical Oncology · 2009 · 256 citations

Urology, Genitourinary Cancer, Kidney Research +8

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

Joaquim Bellmunt, Cezary Szczylik, Jay Feingold et al. · Annals of Oncology · 2008 · 169 citations

Urology, Genitourinary Cancer, Medicine +8

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella et al. · Blood · 2020 · 165 citations · Full text

Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN)

Janice P. Dutcher, Cezary Szczylik, N. Tannir et al. · Journal of Clinical Oncology · 2007 · 121 citations

Temsr Benefits Pts, Urology, Genitourinary Cancer +15